Increased calcium intake reduces plasma cholesterol and improves vasorelaxation in experimental renal failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 5 54-5, 2003, Pages

  Jolma, Pasi ^a   Kööbi, Peeter ^a   Kalliovalkama, Jarkko ^a,b   Kähönen, Mika ^a,b   Fan, Meng ^a   Saha, Heikki ^b   Helin, Heikki ^b   Lehtimäki, Terho ^b   Pörsti, Ilkka ^a,b,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Endothelium; Phosphate; Resistance artery; Smooth muscle

Indexed keywords

ACETYLCHOLINE; ANTIBIOTIC AGENT; BUPRENORPHINE; CALCIUM; CEFUROXIME; CHOLESTEROL; DIAZEPAM; HIGH DENSITY LIPOPROTEIN; KETAMINE; LOW DENSITY LIPOPROTEIN; METRONIDAZOLE; NITROPRUSSIDE SODIUM; NORADRENALIN BITARTRATE; PHOSPHATE BINDING AGENT; POTASSIUM; URETHAN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; LIPID METABOLISM; MALE; MESENTERY BLOOD VESSEL; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; RAT STRAIN; RESISTANCE BLOOD VESSEL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASODILATATION;

EID: 0142232047     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01148.2002     Document Type: Article

References (38)

1. Amann K and Ritz E. Cardiac structure and function in renal disease. Curr Opin Nephrol Hypertens 5: 102-106, 1996.
2. Attman PO, Samuelsson O, and Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573-592, 1993.
3. Bidani AK, Griffin KA, Plott W, and Schwartz MM. Genetic predisposition to hypertension and microvascular injury in the remnant kidney model. J Lab Clin Med 121: 284-291, 1993.
4. Bohlen HG. Localization of vascular resistance changes during hypertension. Hypertension 8: 181-183, 1986.
5. Brown AJ, Dusso A, and Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 277: F157-F175, 1999.
6. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, and Dzau VJ. Impaired vasodilatation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 86: 228-234, 1990.
7. Denke MA, Fox MM, and Schulte MC. Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. J Nutr 123: 1047-1053, 1993.
8. Griffin KA, Picken M, and Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4: 2023-2031, 1994.
9. Griffin KA, Picken MM, Churchill M, Churchill P, and Bidani AK. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 11: 497-506, 2000.
10. Hayakawa H and Raij L. Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. J Hypertens 17: 611-619, 1999.
11. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29: 641-649, 1997.
12. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, and Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10-E17, 2000.
13. Kalliovalkama J, Jolma P, Tolvanen JP, Kähönen M, Hutrio-Kähönen N, Saha H, Tuorila S, Moilanen E, and Pörsti I. Potassium channel-mediated vasorelaxation is impaired in experimental renal failure. Am J Physiol Heart Circ Physiol 277: H1622-H1629, 1999.
14. Karanja N, Morris CD, Illingworth DR, and McCarron DA. Plasma lipids and hypertension: response to calcium supplementation. Am J Clin Nutr 45: 60-65, 1987.
15. Liang K and Vaziri ND. Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure. Am J Physiol Endocrinol Metab 283: E676-E681, 2002.
16. Luke RG. Chronic renal failure-a vasculopathic state. N Engl J Med 339: 841-843, 1998.
17. Morris STW, McMurray JJV, Spiers A, and Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 60: 1077-1082, 2001.
18. Mougenot N, Lesnik P, Ramirez-Gil JF, Nataf P, Diczfalusy U, Chapman MJ, and Lechat P. Effect of the oxidation state of LDL on the modulation of arterial vasomotor response in vitro. Atherosclerosis 133: 183-192, 1997.
19. Mulvany MJ and Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26, 1977.
20. O'Connel BJ and Genest J. High-density lipoproteins and endothelial function. Circulation 104: 1978-1983, 2001.
21. O'Rourke M and Docherty JR. Effects of a high-cholesterol diet on vascular and endothelial function in rat aorta. Pharmacology 56: 1-6, 1998.
22. Panza JA, Quyyumi AA, Brush JE Jr, and Epstein SE. Abrnomal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22-27, 1990.
23. Rabelink TJ and Koomans HA. Endothelial function and the kidney. Drugs 53: 11-19, 1997.
24. Reinharth TA, Horst RL, Orf JW, and Hollis BW. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 58: 91-98, 1984.
25. Rosendorff C. Effects of LDL cholesterol on vascular function. J Hum Hypertens 16, Suppl 1: S26-S28, 2002.
26. Rostand SG and Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56: 383-392, 1999.
27. Schleiffer R, Pernot F, and Jones R. Endothelium is a target organ of parathyroid secretions in genetic hypertensive rats. Horm Metab Res 27: 16-18, 1995.
28. Slatopolsky E, Brown A, and Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37, Suppl 2: S54-S57, 2001.
29. Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, and Baron AD. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 96: 3287-3293, 1997.
30. Suo M, Kalliovalkama J, Pörsti I, Jolma P, Tolvanen JP, Vuolteenaho O, and Ruskoaho H. N(G)-nitro-L-arginine methyl ester-induced hypertension and natriuretic peptide gene expression: inhibition by angiotensin II type 1 receptor antagonism. J Cardiovasc Pharmacol 40: 478-486, 2002.
31. Tesfamariam B and Halpern W. Endothelium-dependent and endothelium-independent vasodilatation in resistance arteries from hypertensive rats. Hypertension 11: 440-444, 1988.
32. Terzi F, Beaufils H, Laouari D, Burtin M, and Kleinknecht C. Renal effects of anti-hypertensive drugs depends on sodium diet in the excision remnant kidney model. Kidney Int 42: 354-363, 1992.
33. Van Guldener C, Lambert J, Janssen MJFM, Donker AJM, and Stehouwer CDA. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic hemodialysis patients. Nephrol Dial Transplant 12, Suppl 2: 14-18, 1997.
34. Vaskonen T, Mervaala E, Sumuvuori V, Seppänen-Laakso T, and Karppanen H. Effects of calcium and plant sterols on serum lipids in obese Zucker rats on a low fat diet. Br J Nutr 87: 239-245, 2002.
35. Vaziri ND, Liang K, and Parks JS. Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 59: 2192-2196, 2001.
36. Vaziri ND, Ni Z, Oveisi F, Liang K, and Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 39: 135-141, 2002.
37. Yacowitz H, Fleischman AI, and Bierenbaum ML. Effects of oral calcium upon serum lipids in man. Br Med J 1: 1352-1354, 1965.
38. Ylitalo P, Hepp R, Oster P, Möhring J, and Gross F. Effects of varying sodium intake on blood pressure and renin-angiotensin system in subtotally nephrectomized rats. J Lab Clin Med 88: 807-816, 1976.